Telehealth Clinic Gross Margin: What a Cash-Pay DTC Rx Model Can Actually Expect

A well-run cash-pay DTC compounding telehealth clinic can typically target a gross margin in the range of 60-75% once the full cost of goods is counted. Publicly traded DTC health peers such as Hims & Hers have reported gross margins in roughly the 70-80% band, which is a useful reference ceiling for a mature subscription Rx model rather than a number to assume on day one. The drivers that move it most are compounded drug cost, provider review, shipping, and payment processing.

That headline number hides a lot. Two clinics selling the same category at the same price can post very different margins depending on how efficiently orders get fulfilled, how many refills each patient completes, and how their platform bills them. This piece breaks the COGS stack down line by line, separates gross margin from the contribution margin that actually determines whether you make money, and shows where operators quietly leak points.

What is a good gross margin for a telehealth clinic?

For a cash-pay DTC compounding clinic, an illustrative healthy range is roughly 60-75% gross margin after drug cost, provider review, shipping, and processing. Public DTC health peers have reported margins in roughly the 70-80% band. Treat that as a reference ceiling for a well-run, refill-heavy subscription model, not a floor you can assume before you have volume.

Gross margin here means revenue minus the direct cost to fulfill an order. It excludes marketing, salaries not tied to fulfillment, and overhead. A new clinic often starts lower than 60% because early order volume is thin, drug pricing per unit is worse without scale, and provider review is a fixed-ish cost spread over few orders. Margin tends to climb as refill volume grows and per-order costs get diluted. Before you set targets, it helps to model the whole picture in telehealth clinic unit economics, because gross margin is only the top layer of that model.

What is the difference between gross margin and contribution margin?

Gross margin is revenue minus cost of goods sold. Contribution margin subtracts one more thing: your customer acquisition cost, allocated per patient. This is the single most common confusion operators make, and it is expensive, because a clinic can show a strong gross margin and still lose money on every patient it acquires.

Here is the trap. Suppose an order carries a 70% gross margin. Impressive on a slide. Now suppose you paid a blended CAC to acquire that patient, and the patient cancels after one or two refills. Once you spread CAC across the small number of orders that patient actually completed, contribution margin can go negative. The fix is not a better gross margin, it is either a lower CAC or more refills per patient, which is a retention problem. Judge the business on contribution margin and lifetime value, using real figures from CAC and LTV benchmarks for 2026, not on gross margin alone. Gross margin tells you whether the product is fundamentally profitable to fulfill. Contribution margin tells you whether the growth engine is.

What line items make up telehealth clinic COGS?

The recurring COGS stack for one compounding telehealth order is: the compounded drug cost billed by the 503A pharmacy, the provider or clinical review cost for the licensed prescriber who approves the order, shipping and cold-chain, payment processing, and the platform or fulfillment software fee per order. Marketing and CAC are not COGS.

Line by line:

1. Compounded drug cost. What the 503A pharmacy charges you to compound and fill. This is usually the largest single COGS line. It varies by active ingredient, dose, and volume commitment, and it is where scale pricing matters most. See compounded Rx pricing and margins for how this line behaves across categories.
2. Provider and clinical review. A licensed provider approves every order. This is a real, recurring cost, whether the provider is employed, contracted, or routed through a clinical group. It is also non-negotiable: no clinical review, no legitimate prescription.
3. Shipping and cold-chain. Standard parcel for oral and topical categories, and validated cold-chain packaging for temperature-sensitive injectables. Cold-chain adds packaging, dry ice or gel packs, and expedited service, which is why injectable categories carry a heavier shipping line.
4. Payment processing. The card and gateway fees on each charge, typically a low-single-digit percentage plus a fixed per-transaction fee. Subscription billing helps here because recurring charges are cheaper to run than repeated cold acquisitions.
5. Platform and fulfillment software. The per-order cost of the software that runs intake, compliance, and routing into the pharmacy. How this is priced matters a lot to margin predictability, which we cover below.

What does a gross-margin bridge look like?

A gross-margin bridge starts at 100% of revenue and subtracts each COGS line to arrive at gross margin. The table below is illustrative, using representative percentage-of-revenue ranges for a single cash-pay compounding order. Your real numbers will differ by category, dose, and pharmacy contract, so treat these as directional, not quoted.

COGS line item	Illustrative % of revenue	What moves it
Compounded drug cost (503A pharmacy)	~15-30%	Active ingredient, dose, volume pricing
Provider / clinical review	~5-12%	Employed vs contracted, orders per provider hour
Shipping & cold-chain	~3-10%	Oral/topical vs injectable, carrier, packaging
Payment processing	~3-5%	Card mix, chargebacks, subscription vs one-time
Platform / fulfillment software	~2-6%	Flat per-order vs percentage-of-value pricing
Gross margin (remaining)	~40-72%	Fulfillment efficiency, category mix, refill volume

Read the bridge as a range, not a forecast. A lean oral category with cheap actives and standard shipping can sit near the top of the gross-margin range. A cold-chain injectable with a costly active can sit closer to the bottom. The point of the bridge is not the exact figure, it is seeing which line you can actually influence.

How does fulfillment efficiency affect margin?

Fulfillment efficiency is the quiet margin lever. The same order can cost meaningfully more or less depending on how much manual work sits between checkout and the pharmacy, how many orders fail and get reworked, and how many refills flow automatically versus needing a fresh intake. Operators who fix this recover points without raising prices.

Three efficiency drivers dominate. First, order routing: an order that flows straight from storefront to pharmacy with automated intake and compliance checks costs less to process than one stitched together by a person copying details between systems. See subscription refill revenue for why automated refills are the highest-margin orders you run, because the acquisition work is already done and the clinical and fulfillment steps are lighter on a continuing patient. Second, error rate: rejected or mis-routed orders get reworked, and rework is pure cost. Third, provider throughput: how many orders a provider can review per hour directly sets the clinical review line. neolife exists to compress this middle layer, sitting on top of the compounding pharmacy a clinic already uses and automating the dispatch into it, so you are not paying people to move data by hand.

How does category mix change gross margin?

Category mix changes both the drug cost and the shipping lines, so your blended gross margin is a weighted average across what you sell. Simple oral and topical categories with inexpensive actives and standard shipping tend to protect margin. Cold-chain injectables carry higher packaging and shipping cost. A single-category clinic is also margin-fragile if that one category faces a supply or regulatory shift.

This is why diversification is a margin strategy, not just a growth strategy. A clinic that lives entirely on one compounded category is exposed to that category's drug cost, its refill behavior, and its regulatory weather all at once. Compounded GLP-1, for example, sits under an unusually active FDA compounding picture, so anchoring your entire margin on it is a concentration risk (see the FDA's compounding laws and policies). Non-controlled 503A categories are the safer default to build around. Blending a few categories smooths the drug-cost line, stabilizes shipping mix, and lowers the odds that one shock takes out your whole margin. The playbook is in protect margins with category diversification.

How does platform pricing affect margin predictability?

Platform pricing affects not just how big the software line is, but how predictable your margin stays as you grow. A percentage-of-order-value take-rate rises with your average order value, so it scales against you as you succeed and can quietly compress margin on higher-priced orders. A flat per-order fee behaves like a known, capped line in your COGS stack.

There is a compliance dimension too. Fee structures tied to the value of a prescription, or to a share of the pharmacy's take, raise fee-splitting and anti-kickback questions that value-based models invite and flat models sidestep. neolife prices as flat FMV SaaS plus a per-order buy-down. That means your platform cost per order is a predictable, flat number you can model years out, not a percentage that grows as your order values climb. Pharmacies are free on the platform. The practical benefit for margin planning is simple: when the software line is flat per order, your gross-margin bridge holds its shape as volume scales, instead of the software line eating a bigger slice on every price increase.

What margin should a new clinic plan for?

A new cash-pay compounding clinic should plan for gross margin below the mature range at first, then improving. Early on, thin volume means worse per-unit drug pricing, fixed provider capacity spread over few orders, and less refill flow, so starting nearer the low end of the illustrative 60-75% band, or below it, is normal. Margin improves as refills grow and fulfillment tightens.

Set a realistic ramp rather than assuming the 70-80% peer ceiling from day one. Track gross margin monthly and watch three things: the drug-cost line as you gain volume pricing, the share of orders that are automated refills versus new acquisitions, and your error and rework rate. If gross margin is healthy but the business still loses money, the problem is almost always CAC or retention, not COGS, which sends you back to contribution margin and LTV, not to renegotiating the pharmacy. Keep the two numbers separate in every board update, because conflating them is how operators mistake a growth problem for a margin problem.

neolife is the fulfillment rail underneath all of this. It sits on top of the compounding pharmacy you already use, keeps a licensed provider in the loop on every order, and lets you keep your own storefront and own your patient data as the system of record, so you can add pharmacies without a rip-and-replace. Priced as flat FMV SaaS plus a per-order buy-down, it keeps the software line in your margin stack predictable as you scale. If you want to pressure-test your own gross-margin bridge against a real fulfillment setup, talk to us.

This article is educational and not legal, medical, financial, or regulatory advice. Figures are illustrative ranges, not quotes or guarantees. Verify pricing, margins, and compliance obligations with your pharmacy partners, licensed providers, and qualified counsel before acting.